Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV130
- Development stage
- Phase 3
- Lead developer
- Inmunotek
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Sublingual, Intranasal
01
Overview
MV130 is a sublingual bacterial vaccine composed of whole-cell heat-inactivated bacteria, designed to prevent recurrent respiratory tract infections (RTIs) and lower respiratory tract infections. It is classified as a trained immunity-based vaccine (TIbV), which induces trained immunity and provides non-specific protection against various respiratory pathogens. The formulation consists of approximately 90% selected Gram-positive strains (Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus pneumoniae) and 10% Gram-negative strains (Klebsiella pneumoniae, Haemophilus influenzae, Moraxella catarrhalis). MV130 is administered via the sublingual mucosa using a metered pump spray or as an intranasal suspension. Clinical studies have shown that MV130 reduces the frequency of recurrent RTIs in both adults and children at risk, including those with common variable immunodeficiency (CVID) or chronic obstructive pulmonary disease (COPD). The drug is developed by Inmunotek[1][3][4][5].
- Brand names
- Bactek
- Other names
- mv130mv-130mv 130bactek
Beyond the preview
Go deeper on MV130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV130.